Citations

Showing 10 of 108083 citations.

Setting the stage for universal financial distress screening in routine cancer care
Khera, Nandita , Holland, Jimmie C., Griffin, Joan M.

Mayo Clinic

Cancer | August 17, 2017 | Volume: 123 | Issue: 21 | Pages: 4092-4096

10.1002/cncr.30940 | PMID 28817185 Get It

Financial burden from cancer treatment is increasingly being recognized as a threat to optimal access, quality, and outcomes of cancer care for patients. Although research in the area is moving at a fast pace, multiple questions remain unanswered, such as how to practically integrate the assessment and management of financial burden into routine health care delivery for patients with cancer. Although psychological distress screening for patients undergoing cancer treatment now is commonplace, the authors raise the provocative idea of universal screening for financial distress to identify and assist vulnerable groups of patients. Herein, the authors outline the arguments to support screening for financial burden in addition to psychological distress, examining it as an independent patient‐reported outcome for all patients with cancer at various time points during their treatment. The authors describe the proximal and downstream impact of such a strategy and reflect on some challenges and potential solutions to help integrate this concept into routine cancer care delivery. Cancer 2017;123:4092–4096. © 2017 American Cancer Society.
Second‐line treatment in patients with pancreatic ductal adenocarcinoma: A meta‐analysis
Sonbol, Mohamad Bassam , Firwana, Belal , Wang, Zhen , Almader‐Douglas, Diana , Makhoul, Issam , Ramanathan, Ramesh K., Ahn, Daniel H. , Bekaii‐Saab, Tanios , Ahn, Daniel H , Sonbol, Mohamad B , Bekaii-Saab, Tanios S , Borad, Mitesh J.

Mayo Clinic

Cancer | August 17, 2017 | Volume: 123 | Issue: 23 | Pages: 4680-4686

10.1002/cncr.30927 | PMID 28817187 Get It

BACKGROUNDThere are limited therapeutic options for treatment‐refractory pancreatic ductal adenocarcinoma (PDAC), with a paucity of data to support the best option after progression on gemcitabine‐based regimens. The authors performed a meta‐analysis to determine the effectiveness of adding oxaliplatin (OX) or various irinotecan formulations to a fluoropyrimidine (FP) after first‐line treatment progression in patients with PDAC.METHODSDifferent databases, including PubMed, EMBASE, and Cochrane, were searched to identify randomized controlled trials comparing FP monotherapy versus FP combination therapy that included either oxaliplatin (FPOX) or various irinotecan formulations (FPIRI) in patients with PDAC who progressed after first‐line treatment. Secondary analyses were planned to assess the effectiveness of FPOX and FPIRI compared with FP. Outcomes of interest included overall survival (OS) and progression‐free survival (PFS).RESULTSFive studies with 895 patients were identified. Patients randomized to receive FPIRI/FPOX had a significantly improved PFS and a trend toward improved OS compared with those who received FP monotherapy. When comparing FPIRI with FP, there was an improvement in both PFS (hazard ratio, 0.64; 95% confidence interval, 0.47‐0.87; P = .005) and OS (hazard ratio, 0.70; 95% confidence interval, 0.55‐0.89; P = .004) in patients who received the combination. Conversely, FPOX produced only a modest improvement in PFS with no improvement in OS.CONCLUSIONSCombination chemotherapy with OX or various IRI formulations appears to improve PFS compared with single‐agent FP. FPIRI, but not FPOX, appears to confer an OS advantage. The combination of FP with irinotecan formulations appears to be the appropriate next line of treatment upon progression after gemcitabine‐based chemotherapy regimens. Cancer 2017;123:4680‐4686. © 2017 American Cancer Society.
Diagnostic performance of unenhanced computed tomography and 18F‐fluorodeoxyglucose positron emission tomography in indeterminate adrenal tumours
Delivanis, Danae A. , Atwell, Thomas D. , Schmit, Grant D. , Eiken, Patrick W. , Natt, Neena, Erickson, Dana , Maraka, Spyridoula , Nathan, Mark A., Maraka, Spyridoula , Bancos, Irina , Young, William F.

Mayo Clinic

Clinical Endocrinology | August 17, 2017 | Volume: 88 | Issue: 1 | Pages: 30-36

10.1111/cen.13448 | PMID 28815667 Get It

SummaryObjectiveEvidence on the diagnostic performance of adrenal imaging is limited. We aimed to assess the diagnostic performance of unenhanced computed tomography (CT) and 18F‐fluorodeoxyglucose (18FDG) positron emission tomography (PET)/CT imaging in a high‐risk population for adrenal malignancy using an optimal reference standard.DesignRetrospective cohort study.MethodsImaging studies of patients with adrenal nodules who underwent adrenal biopsy and/or adrenalectomy between 1994 and 2014 were reviewed and compared to the reference standard of histology. Eighty % of patients presented with known or suspected extra‐adrenal malignancy.ResultsUnenhanced abdominal CT was performed in 353 patients with adrenal lesions; median size was 3 (0.7‐15) cm and median radiodensity was 33 (−21‐78) Hounsfield units (HU). Radiodensity of >10 HU diagnosed malignancy with a sensitivity of 100%, specificity of 33%, positive predictive value (PPV) of 72% and negative predictive value (NPV) of 100%. 18FDG‐PET/CT was performed in 89 patients; median tumour size was 2.1 (0.7‐9.2) cm. Maximum standardized uptake (SUV max) was higher in malignant lesions when compared to benign lesions (median=10 [2.3‐29.4] vs 3.7 [1.4‐24.5], respectively, P<.0001). Similarly, median SUV max lesion to SUV max liver ratio (ALR) in malignant lesions was higher than in benign lesions (median=3 [0.74‐13.4] vs 1.2 [0.5‐6.6], respectively, P<.0001). 18FDG‐PET/CT ALR >1.8 diagnosed malignancy with a sensitivity of 87%, specificity of 84%, PPV of 85% and NPV of 86%.ConclusionNoncontract CT radiodensity of ≤10 HU excludes malignancy even in a high‐risk population. For indeterminate adrenal lesions, given a superior specificity, 18FDG‐PET/CT could be considered as a second stage imaging study.
Fatty allograft and cardiovascular outcomes after liver transplantation
Bhanji, Rahima A. , Watt, Kymberly D.

Mayo Clinic

Liver Transplantation | August 17, 2017 | Volume: 23 | Issue: S1 | Pages: S76-S80

10.1002/lt.24843 | PMID 28815935 Get It

Pharmacology and Perioperative Considerations for Diabetes Mellitus Medications
Aniskevich, Stephen , Irizarry-Alvarado, Joan M., Renew, Johnathan R, Aniskevich, Stephen , Renew, J. Ross , Chadha, Ryan

Mayo Clinic

Current Clinical Pharmacology | August 17, 2017 | Volume: 12 | Issue: 3 | Pages: 157-163

10.2174/1574884712666170810115847 | PMID 28799484 Get It

Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant
Jacob, Deepti A., Busciglio, Irene, Burton, Duane, Halawi, Houssam , Oduyebo, Ibironke, Rhoten, Deborah, Ryks, Michael, Harmsen, William S. , Camilleri, Michael , Jacob, Deepti

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | August 17, 2017 | Volume: 313 | Issue: 5 | Pages: G505-G510

10.1152/ajpgi.00197.2017 | PMID 28814387 Get It

Aprepitant, an NK1 receptor antagonist, is approved for the treatment of chemotherapy-induced or postoperative emesis by blocking NK1 receptors in the brain stem vomiting center. The effects of NK1 receptors on gastric functions and postprandial symptoms in humans are unclear; a single, crossover study did not show a significant effect of aprepitant on gastrointestinal transit. Our aim was to compare, in a randomized, double-blind, placebo-controlled, parallel-group study (12 healthy volunteers per group), the effects of aprepitant vs. placebo on gastric emptying of solids (by scintigraphy) with a 320-kcal meal, gastric volumes (GVs; fasting and accommodation by single photon emission-computed tomography ), satiation [maximum tolerated volume (MTV)], and symptoms after a dyspeptogenic meal of Ensure. Aprepitant (125 mg on day 1, followed by 80 mg on days 2–5) or placebo, one tablet daily, was administered for 5 consecutive days. Statistical analysis was by unpaired rank sum test, adjusted for sex difference and body mass index. To assess treatment effects on symptoms, we incorporated MTV in the model. Aprepitant increased fasting, postprandial, and accommodation GV and tended to increase volume to fullness and MTV by ~200 kcal. However, aprepitant increased aggregate symptoms, nausea, and pain scores after ingestion the MTV of Ensure. There was no significant effect of aprepitant on gastric half-emptying time of solids. We conclude that NK1 receptors are involved in the control of GV and in determining postprandial satiation and symptoms. Further studies of the pharmacodynamics and therapeutic role of NK1 receptor antagonists in patients with gastroparesis and dyspepsia are warranted. NEW & NOTEWORTHY Aprepitant increases fasting, postprandial, and accommodation gastric volumes. Aprepitant increases volume to fullness and maximum tolerated volume during a nutrient drink test. NK1 receptors are involved in the control of gastric volume and in determining postprandial satiation and symptoms.
High-Resolution, Accurate-Mass (HRAM) Mass Spectrometry Urine Steroid Profiling in the Diagnosis of Adrenal Disorders
Hines, Jolaine M., Bancos, Cristian, Singh, Raman Deep , Avula, Aditya V, Grebe, Stefan K., Singh, Raman D., Bancos, Irina , Young, William F. , Singh, Ravinder J.

Mayo Clinic

Clinical Chemistry | August 16, 2017 | Volume: 63 | Issue: 12 | Pages: 1824-1835

10.1373/clinchem.2017.271106 | PMID 28814383 Get It

Abstract BACKGROUND Steroid profiling is a promising diagnostic tool with adrenal tumors, Cushing syndrome (CS), and disorders of steroidogenesis. Our objective was to develop a multiple-steroid assay using liquid-chromatography, high-resolution, accurate-mass mass spectrometry (HRAM LC-MS) and to validate the assay in patients with various adrenal disorders. METHODS We collected 24-h urine samples from 114 controls and 71 patients with adrenal diseases. An HRAM LC-MS method was validated for quantitative analysis of 26 steroid metabolites in hydrolyzed urine samples. Differences in steroid excretion between patients were analyzed based on Z-score deviation from control reference intervals. RESULTS Limits of quantification were 20 ng/mL. Dilution linearity ranged from 80% to 120% with means of 93% to 110% for all but 2 analytes. Intraassay and interassay imprecision ranged from 3% to 18% for all but 1 analyte. Control women had lower excretion of androgen and glucocorticoid precursors/metabolites than men (P &lt; 0.001), but no difference in mineralocorticoids was seen (P = 0.06). Androgens decreased with age in both sexes (P &lt; 0.001). Compared with patients with adrenocortical adenoma (ACA), patients with adrenocortical carcinoma (ACC) had 11 steroids with increased Z scores, especially tetrahydro-11-deoxycortisol (14 vs 0.5, P &lt; 0.001), pregnanetriol (7.5 vs −0.4, P = 0.001), and 5-pregnenetriol (5.4 vs −0.4, P = 0.01). Steroid profiling also demonstrated metabolite abnormalities consistent with enzymatic defects in congenital adrenal hyperplasia and differences in pituitary vs adrenal CS. CONCLUSIONS Our HRAM LC-MS assay successfully quantifies 26 steroids in urine. The statistically significant differences in steroid production of ACC vs ACA, adrenal vs pituitary CS, and in congenital adrenal hyperplasia should allow for improved diagnosis of patients with these diseases.
Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts
Tack, Jan , Corsetti, Maura , Camilleri, Michael , Suzuki, Hidekazu , Talley, Nicholas J. , Törnblom, Hans , Oudenhove, Lukas Van , Corsetti, M , Tack, Jan , Quigley, Eamonn M.M. , Simrén, Magnus

Mayo Clinic

Gut | August 16, 2017 | Volume: 67 | Issue: 8 | Pages: 1425-1433

10.1136/gutjnl-2016-312230 | PMID 28814481 Get It

Background and aims The functional gastrointestinal disorders (FGIDs) are extremely common conditions associated with a considerable personal, social and health economic burden. Managing FGIDs in clinical practice is challenging because of the uncertainty of symptom-based diagnosis, the high frequency of overlap between these conditions and the limited efficacy of available therapies. It has often been argued that successful drug development and management of FGIDs requires knowledge of the underlying pathophysiology. Numerous and highly variable candidate pathophysiological mechanisms have been implicated in the generation of FGID symptoms, but there is no current consensus on how to best define the relevance of these disturbances. Methods A group of international experts on FGIDs developed plausibility criteria that should be fulfilled by relevant pathophysiological mechanisms in FGIDs. Results Five criteria are proposed: (1) the presence of the abnormality in a subset of patients, (2) temporal association between proposed mechanism and symptom(s), (3) correlation between the level of impairment of the mechanism and symptom(s), (4) induction of the symptom(s) by provoking the pathophysiological abnormality in healthy subjects and (5) treatment response by a therapy specifically correcting the underlying disorder or congruent natural history of symptoms and dysfunction in the absence of specific therapy. Based on strength of evidence for these five criteria according to the Grading of Recommendations Assessment, Development and Evaluation system, a plausibility score can be calculated for each mechanism. Conclusion Evaluation of the strength of evidence for candidate pathophysiological abnormalities fulfilling these five plausibility criteria will help to identify the most relevant mechanisms to target for novel diagnostic approaches and for the development of new therapies.
Effects of nicotine on homeostatic and hedonic components of food intake
Stojakovic, Andrea , Espinosa, Enma P, Farhad, Osman T, Lutfy, Kabirullah , Espinosa, Enma Verónica Paez, Stojacovic, Andrea

Mayo Clinic

Journal of Endocrinology | August 16, 2017 | Volume: 235 | Issue: 1 | Pages: R13-R31

10.1530/joe-17-0166 | PMID 28814527 Get It

Chronic tobacco use leads to nicotine addiction that is characterized by exaggerated urges to use the drug despite the accompanying negative health and socioeconomic burdens. Interestingly, nicotine users are found to be leaner than the general population. Review of the existing literature revealed that nicotine affects energy homeostasis and food consumption via altering the activity of neurons containing orexigenic and anorexigenic peptides in the brain. Hypothalamus is one of the critical brain areas that regulates energy balance via the action of these neuropeptides. The equilibrium between these two groups of peptides can be shifted by nicotine leading to decreased food intake and weight loss. The aim of this article is to review the existing literature on the effect of nicotine on food intake and energy homeostasis and report on the changes that nicotine brings about in the level of these peptides and their receptors that may explain changes in food intake and body weight induced by nicotine. Furthermore, we review the effect of nicotine on the hedonic aspect of food intake. Finally, we discuss the involvement of different subtypes of nicotinic acetylcholine receptors in the regulatory action of nicotine on food intake and energy homeostasis.
Counseling Close to Home: Genetic Counselors’ Experiences with their own Family Members
Rust, Laura, Adamsheck, Hallee, Reiser, Catherine A. , Petty, Elizabeth M.

Mayo Clinic

Journal of Genetic Counseling | August 16, 2017 | Volume: 27 | Issue: 1 | Pages: 225-240

10.1007/s10897-017-0138-z | PMID 28815348 Get It

AbstractGenetic counselors are trained to provide personalized genetic information and support to clients and their families. When requests for counseling comes from the counselor's own family member, should that counselor still provide service? There is a paucity of literature regarding genetic counselors counseling their own family members and no specific recommendations regarding how to reply to requests for genetic information from relatives. The purpose of this mixed methods study was to report genetic counselors’ and genetic counseling students’ perspectives and experiences providing genetic counseling to relatives. In the present study, 423 genetic counselors and genetic counseling students completed a 70‐item web‐based survey that explored genetic counselors’ experiences counseling family members outside of a clinic setting. The majority (73%; n = 301/410) of respondents have been asked to provide genetic counseling. Over half (57%; n = 257/423) provided counseling, personalized genetic information or risk assessment to family members. Only a small fraction of respondents (11%; n = 45/420) responded that they received any formal training in their graduate education, or in any other capacity that addressed the issue of how genetic counselors should respond to genetic counseling requests made family members. Those who have were less likely to provide genetic counseling to a family member (p < 0.05). Respondents who provided genetic counseling to relatives were significantly more likely to think their colleagues would do the same. Those who never provided genetic counseling to relatives were more likely to think their colleagues would refer to an unrelated genetic counselor (p < 0.0001). We highlight how our results have clinical and professional implications and provide suggestions to generate discussion among genetic counselors on how they might respond to requests for counseling from family members.